In celebration of National Cancer Prevention Day, Anpac Bio has announced that their cancer differentiation analysis (CDA) liquid biopsy test is now capable of detecting 26 different cancers from a single blood test.
With research validation from over 60,000 cases, Anpac Bio’s CDA test has demonstrated a sensitivity and specificity rate of 75% to 90%. According to the company, the test generates fewer false positives, costs less than traditional testing, and returns results within minutes of sample submission. By analyzing simple, standard blood tests and applying multilevel, multiparameter, diagnostic algorithms, this technology identifies cancer with measurably greater accuracy than most current conventional screening methods.
“Every day, our company hears of other, potential ‘liquid biopsy’ tests that report ‘someday’ may be used to catch cancer,” states Chris Yu, Ph.D., Anpac Bio CEO. “Our CDA technology has been extensively tested, verified, and used daily by dozens of Asia’s most well-respected and renowned medical institutions. We are also generating equally accurate and positive results in the United States. We’re very proud that our CDA devices have advanced well beyond the laboratory and are processing real tests for real people—saving lives every day….Anpac Bio and our medical partners want the world to know: ‘Someday‘ is now!”
According to the company’s website, the test was previously able to detect 20 different cancers, based on 50,000 case studies. Second Military Medical University and Changhai Hospital (in Shanghai, China), alone have submitted more than 4000 lung cancer, esophageal cancer, and control samples to the company.
“Our preliminarily results indicate that CDA technology has better sensitivity and specificity for early diagnosis, as well as [being] potentially a good tool for treatment assessment for lung cancer and esophageal cancer than traditional tumor markers,” reports Jun-Jie Wu, M.D., deputy chief physician, department of oncology, Changhai Hospital. “[CDA] can also play a good role in complementing chest computed tomography screening for pulmonary nodules.”
Two clinical studies of the CDA liquid biopsy technology have been conducted at the department of oncology at Shanghai Changzheng Hospital since 2016. “Initial results indicated that CDA technology has better sensitivity and specificity for early-stage cancer screening than that of traditional tumor markers,” says Yuan Sheng Zang, M.D., study director and deputy professor at the hospital. “The evaluation on the significance of CDA technology in prognosis is ongoing. The existing research data suggests that CDA technology has a good prospect in the field of cancer diagnosis and prognosis.”